This Biotechnology ETF Could Be the Place to Be in a Recession

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is already trouncing basic biotechnology and healthcare ETFs and historical data suggest that even if a recession lingers, ARKG could prove durable. SVB Leerink analyst Geoffrey Porges recently pointed out in a note to clients that...